What Investors Get Wrong About Healthcare in Emerging Markets
By Ali Alqeisi | Strategic Partnerships, Marketing & Communications Manager, Emerging Health International
Picture this.
A healthcare investor sits across from a founding team in Lagos, Karachi, or Amman. The numbers look compelling. Population growth is accelerating. Middle-class expansion is driving demand. Insurance penetration is rising. The market opportunity is, by any measure, enormous.
The investor commits. The project launches. And two years later , the returns disappoint, the model hasn’t scaled, and the exit looks nothing like the projections.
This is not a hypothetical. It is a pattern — one that repeats itself across emerging market healthcare investments with striking regularity.
The opportunity is real. The mistakes are also real. And most of them happen not because investors are uninformed about the market opportunity, but because they are systematically misinformed about the nature of the execution risk.
Here is what the data and the pattern, actually shows.
The Opportunity Is Real. So Is the Misunderstanding
Investors have traditionally been scared away from emerging economies, as they tend to have higher levels of risk and volatility, including political instability, underdeveloped regulatory frameworks, and risks associated with currency fluctuations. These concerns are legitimate. But they are also well-known , and increasingly well-managed.
What is less well-understood is a different category of risk entirely: the execution gap.
Healthcare markets in these countries represent a potential robust return on investment as populations grow and economies burgeon and become increasingly interconnected with global markets. The structural tailwinds are undeniable. Emerging markets are expanding access and insurance coverage — creating a demand environment that simply doesn’t exist in saturated, high-income markets.
But demand is not delivery. And the gap between the two is where most investments quietly fail.
Mistake 1 — Treating Execution as a Footnote
Ask most healthcare investors what they scrutinize most carefully in an emerging market deal. You will hear answers about market size, competitive positioning, regulatory environment, and financial projections.
Execution infrastructure rarely makes the list.
This is a fundamental error. In high-income healthcare markets, execution infrastructure, trained workforces, clinical governance systems, quality frameworks, supply chains, regulatory bodies — is largely assumed. It exists. It functions. It supports implementation.
In emerging markets, this infrastructure is often partial, fragile, or entirely absent. The most carefully designed healthcare model, deployed without the operational systems to support it, does not just underperform. It fails.
Businesses in emerging markets face risks including unreliable infrastructure, political and economic instability, limited and changing regulatory frameworks, limited data, and insufficient or insufficiently trained workforce.
These are not niche concerns. They are the operating environment. And yet investment theses are routinely built on financial models that assume execution will happen — without seriously assessing whether the conditions for execution exist.
Mistake 2 — Confusing Market Growth With Investment Return
In November 2025, healthcare ETFs experienced their largest monthly global inflows in five years, attracting US$6.8 billion across the industry. Investor appetite for healthcare is growing. But appetite and returns are not the same thing.
Emerging market healthcare is particularly vulnerable to the confusion between macro opportunity and micro execution. The headline numbers are compelling — population growth, rising incomes, expanding insurance coverage. They attract capital. But capital deployed into a market with strong demand and weak operational infrastructure does not automatically generate returns.
Mismanaged expectations further strain investor relationships, leading to dissatisfaction and, in some cases, premature exits or failures.
The pattern is consistent: investors enter on the strength of the market story. They exit when the operational reality , workforce gaps, system failures, governance weaknesses — produces results that the market story never accounted for.
Mistake 3 — Underestimating the Workforce Problem
Of all the execution risks in emerging market healthcare, workforce is the most consistently underestimated.
Not the availability of healthcare workers, though that is a genuine challenge. The deeper problem is the absence of the systems that allow available workers to perform consistently.
Budget restrictions that don’t cover the needed investment in workforce, infrastructure, and care solutions are identified as one of the defining challenges of emerging market healthcare over the next two years. But the investment community’s response to this challenge is typically to flag it as a risk factor — not to address it as a design requirement.
The result: healthcare models that are built for a workforce that doesn’t yet exist, or that assume clinical governance structures that were never put in place.
When performance disappoints, the diagnosis is typically “workforce shortage.” The actual diagnosis is more often “workforce without systems” — capable people operating inside an environment that was never designed to support consistent performance.
Mistake 4 — Importing Models Without Adapting Them
There is a particular category of investment failure that deserves its own examination: the imported model problem.
Investors, often advised by consultants with high-income market experience — deploy healthcare models that have worked elsewhere without adequately accounting for the contextual differences that determine whether they will work here.
Health authorities in emerging markets constantly call for the implementation of a preventive approach and the strengthening of primary care but struggle to implement effective measures.
The struggle is not conceptual. The concept , preventive care, primary care strengthening , is widely understood and broadly endorsed. The struggle is implementation in contexts where the supporting infrastructure, the workforce capability, and the community trust that make these models work in high-income settings are not yet in place.
Deploying a model without adapting it to its implementation environment is not a conservative investment strategy. It is a high-risk one — dressed up as proven practice.
Mistake 5 — Measuring the Wrong Things
Investment performance in emerging market healthcare is frequently assessed against metrics designed for different markets.
Patient volume. Revenue per bed. Return on assets. These measures have their place. But in markets where the fundamental challenge is building functioning systems from fragile foundations, they capture outcomes while missing the drivers.
The traditional siloed approach to healthcare policy is no longer adequate to address complex issues. Instead, a holistic and multidisciplinary approach that encompasses the interconnectedness of healthcare with other sectors is essential.
The same principle applies to investment assessment. A healthcare project that is hitting volume targets while running on dysfunctional operational systems is not a healthy investment. It is a fragile one — one operational crisis away from a performance collapse that the volume numbers never predicted.
The investors who generate consistent returns in emerging market healthcare are not the ones who found better markets. They are the ones who found, or built, better execution partners.
What Successful Emerging Market Healthcare Investment Actually Looks Like
The J.P. Morgan Healthcare Conference panel on emerging market investment made a point that deserves wider circulation: “Illness is universal, healthcare is not, but if we reimagine the way we all show up to invest in healthcare and technology in emerging markets, I think we can change that.”
Reimagining how investment shows up means three things in practice:
Due diligence that includes execution infrastructure. Not just market size and competitive positioning — but honest assessment of the operational systems, governance structures, and workforce capacity that will determine whether the model actually works.
Investment structures that fund implementation, not just launch. The gap between a working model and a launched model is not closed by capital alone. It requires sustained operational support, iterative improvement, and the willingness to stay through the difficult middle period when new systems are being embedded.
Partners who understand the context. The most important due diligence question in emerging market healthcare is not “does this model work?” It is “does this partner understand what it takes to make this model work here?” Global expertise without local execution capability is not a credible partner. Local presence without global standards is not either.
The investment opportunity in emerging market healthcare is real — and growing. Emerging markets are expanding access and insurance coverage in ways that create demand environments that don’t exist elsewhere.
But opportunity and return are separated by execution. And execution, in emerging markets, is not a given. It is a discipline — one that requires the right partners, the right infrastructure, and the right approach to implementation.
The investors who understand that are the ones who will capture the opportunity that the rest are leaving on the table.
References
- Bay Area Global Health Alliance / J.P. Morgan Healthcare Conference (2024). Reimagining Healthcare in Emerging Markets: The Future of Healthcare Innovation and Investment. https://bayareaglobalhealth.org/alliance-news/reimagining-healthcare-in-emerging-markets-the-future-of-healthcare-innovation-and-investment/
- Speyside Group (2024). 2024-2025 Emerging Markets Healthcare Outlook. https://speyside-group.com/news-insights/2024-2025-emerging-markets-healthcare-outlook
- BlackRock / iShares (2026). Healthcare Making a Comeback? https://www.blackrock.com/au/insights/ishares/2026-comeback-year-for-healthcare
- The Top Voices (2025). Investment Trends in Healthcare Startups 2025–2035. https://thetopvoices.com/story/clarification-on-investment-trends-in-healthcare-startups-2025-2035
- egy-forex.com (2025). Is Healthcare a Good Investment in 2025? Key Sectors, Risks and Opportunities. https://egy-forex.com/is-healthcare-a-good-investment-in-2025-key-sectors-risks-and-opportunities/
Ali Alqeisi is Strategic Partnerships, Marketing & Communications Manager at Emerging Health International — a healthcare transformation partner working across emerging markets to bridge the gap between strategy and real-world implementation.
For more insights on healthcare transformation in emerging markets, explore our Insights section or read our previous articles: